HB
HBPCF.US Helix BioPharma Corp
- Market cap
- USD 58.8M
- P/E
- -
- P/B
- 5.90x
- ROE
- -23.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jul 2026.
Is HBPCF.US undervalued?
Graham numberThe Graham number of Helix BioPharma Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Helix BioPharma Corp fundamental analysis
No fundamental analysis for Helix BioPharma Corp yet.
Helix BioPharma Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Helix BioPharma Corp
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II…
Full company profileHelix BioPharma Corp financial statements
Helix BioPharma Corp annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 |
| Gross Profit | -130K | -167K | -56.0K | -212K | -173K | -12.0K | -13.0K | -10.1K | -7.22K | - |
| Operating Income | -10.2M | -8.54M | -7.49M | -8.59M | -9.61M | -6.54M | -6.33M | -9.37K | -5.00M | -3.64M |
| EBITDA | -10.1M | -8.38M | -6.72M | -8.38M | -9.07M | -6.53M | -6.31M | 4.76K | -5.00M | -3.17M |
| Net Income | -10.1M | -8.63M | -7.53M | -8.99M | -8.04M | -6.56M | -6.29M | -9.26K | -5.00M | -3.35M |
| EPS | -0.11 | -0.09 | -0.07 | -0.07 | -0.06 | -0.04 | -0.03 | 0.00 | -0.09 | -0.04 |
| Balance Sheet | ||||||||||
| Total Assets | 2.19M | 1.15M | 940K | 4.91M | 4.07M | 3.73M | 1.03M | 1.49M | 18.7M | 19.4M |
| Total Liabilities | 2.20M | 2.67M | 4.22M | 1.93M | 5.46M | 3.41M | 1.87M | 1.58M | 3.20M | 5.17M |
| Shareholders' Equity | -17.0K | -1.53M | -3.28M | 2.39M | -1.39M | 319K | -844K | -90.0K | 15.5M | 14.2M |
| Cash & Short-term Investments | 897K | 366K | 206K | 4.24M | 3.57M | 3.25M | 808K | 1.08M | 64.6K | 804K |
| Total Debt | - | - | - | 159K | 3.61M | 2.47M | - | - | 333K | 4.16M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -9.30M | -7.52M | -5.53M | -10.8M | -9.30M | -6.51M | -5.53M | -5.22M | -4.00M | -4.32M |
| Capital Expenditure | 382K | 53.0K | 4.00K | 16.0K | 0.00 | 0.00 | 10.0K | 14.0K | 1.44K | 0.00 |
| Free Cash Flow | -9.68M | -7.58M | -5.54M | -10.8M | -9.30M | -6.51M | -5.54M | -5.23M | -4.00M | -4.32M |
| Ratios | ||||||||||
| ROE | - | - | - | -375.3% | - | -2,057.4% | - | - | -32.3% | -23.6% |
| ROA | -459.9% | -752.0% | -800.6% | -183.1% | -197.7% | -176.0% | -611.3% | -0.6% | -26.7% | -17.3% |
| Debt to Equity | - | - | - | 0.07x | - | 7.74x | - | - | 0.02x | 0.29x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Helix BioPharma Corp dividends
Helix BioPharma Corp has not paid dividends in the last 10 fiscal years.
Last stock split: 1:5 on Aug 16, 2024.
Who owns Helix BioPharma Corp
- Insiders 38.83%
- Institutions 0.00%
- Public & others 61.17%
- Shares outstanding 76.4M
- Free float 46.7M
Helix BioPharma Corp company profile
- Company name
- Helix BioPharma Corp
- Ticker
- HBPCF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- July
- Address
- 1055 West Georgia Street, Vancouver, BC, Canada, V6E 3P3
- Phone
- 905-841-2300
- Website
- helixbiopharma.com
About Helix BioPharma Corp
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; LDOS007, which is in phase Ib/II for the treatment of lung cancer; and CEACAM6-targeting technology, provides multi-specific antibody-drug conjugates (ADCs) for gastrointestinal cancers and radioligand therapeutics for pancreatic cancer. It has collaboration agreements with Moffitt Cancer Center to investigate and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to investigate the effects of L DOS47 on tumor acidity using imaging technologies. The company has an agreement with metaShape Pharma AG for covering LEUMUNA, within the field of adipose tissue-related and metabolic diseases; and GEMCEDA, an oral gemcitabine prodrug combined with cedazuridine in preclinical development for the treatment of solid tumors. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.
Helix BioPharma Corp management
9- Dr. Thomas Mehrling M.D., Ph.D.CEO & Director
- Mr. Rohit Babbar C.A., CPAChief Financial Officer
- Ms. Veronika KandzioraChief Operating Officer
- Dr. Davide Guggi Ph.D.Chief Technology Officer
- Mr. Jacek AntasCorporate Secretary
- Ms. Helen MiddletonGeneral Counsel
- Dr. Jessica Kourniaktis DPHILDirector of Communications
- Dr. Markus Loeffler M.B.A., M.D.Chief Medical Officer
- Ms. Natalia L. ButterworthCorporate Secretary